Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery
Status:
Not yet recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This is a window-of-opportunity study for patients with resectable Merkel Cell Carcinoma.
The aim of this study is to test the activity of a course of chemo-immunotherapy followed by
surgery in patients with operable Merkel cell carcinoma.
Participants will receive one cycle of retifanlimab plus platinum-etoposide chemotherapy
prior to their scheduled surgery.